Evelyn Partners Investment Management Europe Ltd Acquires 11,776 Shares of Johnson & Johnson $JNJ

Evelyn Partners Investment Management Europe Ltd grew its holdings in Johnson & Johnson (NYSE:JNJ) by 11,109.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,882 shares of the company’s stock after acquiring an additional 11,776 shares during the quarter. Johnson & Johnson accounts for about 2.1% of Evelyn Partners Investment Management Europe Ltd’s investment portfolio, making the stock its 13th largest holding. Evelyn Partners Investment Management Europe Ltd’s holdings in Johnson & Johnson were worth $1,815,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Evelyn Partners Asset Management Ltd lifted its stake in Johnson & Johnson by 594.5% in the second quarter. Evelyn Partners Asset Management Ltd now owns 12,397 shares of the company’s stock valued at $1,894,000 after buying an additional 10,612 shares in the last quarter. CFC Planning Co LLC lifted its position in Johnson & Johnson by 5.3% in the 2nd quarter. CFC Planning Co LLC now owns 18,280 shares of the company’s stock valued at $2,792,000 after acquiring an additional 926 shares in the last quarter. Mediolanum International Funds Ltd boosted its stake in Johnson & Johnson by 14.0% in the 2nd quarter. Mediolanum International Funds Ltd now owns 426,141 shares of the company’s stock worth $64,948,000 after purchasing an additional 52,199 shares during the period. Legal & General Group Plc increased its holdings in Johnson & Johnson by 6.2% during the 2nd quarter. Legal & General Group Plc now owns 18,917,274 shares of the company’s stock worth $2,889,614,000 after purchasing an additional 1,097,855 shares in the last quarter. Finally, Hillsdale Investment Management Inc. raised its stake in shares of Johnson & Johnson by 1,942.1% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 44,762 shares of the company’s stock valued at $6,837,000 after purchasing an additional 42,570 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $203.88 on Friday. The stock has a market capitalization of $491.21 billion, a PE ratio of 19.68, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $206.94. The firm has a fifty day simple moving average of $188.25 and a 200 day simple moving average of $171.55. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on JNJ. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research report on Monday, October 20th. Raymond James Financial raised their price target on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. UBS Group boosted their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, The Goldman Sachs Group lifted their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $201.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.